Everything and anything I post, is just an OPINION!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can't stop PROFITABLE :)))
000's coming this week, then a BILLION more shares being dumped, then RS
(((( Fully Reporting & Profitable ))))
2015 will be EPIC for Investors, BIG BIG Year!
Mark it ;)
Zero Selloff = $TRONG MDHI PPS
000's coming this week!
If dead means Profitable, Fully Reporting, Rapidly Growing Recurring Revenue UP 533% YOY, Low Float, Zero Debt, Partnered w Costco, programs with Coventry, Medicare, Medicaid, APS, JTT, New Technology, New Employees, and making Acquisitions ??
If that's dead, I'm ALL IN MDHI for 2015 EPIC year :))))
When Financials continue to show increasing REVENUE$, everyone is gonna care:)))
You can't stop Rapidly Growing RECURRING REVENUE, it's all that matter$$$$$$$
The past is the past, MDHI is ALL about the future $$$$$$ 2015 will be game changer.
Hold for 000's, with the BILLIONS o shares they have to dump, it's only a matter of time.
Revenue$ UP 533% YOY, watch n see what 2015 Rev'$ will show on this
Low Float
Fully Reporting
Profitable
Rapidly Increasing Recurring Rev
Costco
Coventry
Medicare
Medicaid
APS
JTT
Acquisition$$$$$$
New Technology
2015 will be EPIC :)))(
lmao, SEC NON ISSUE, Scare tactics won't stop MDHI $ales or REVENUE$$$$, 2015 filing will show it ALL, that's why MDHI CEO Ronnie Adams brought it current, after all he did build a $60 Million Dollar NASDQ company. He's done it again, MDHI is CURRENT & PROFITABLE.
Joe who????
Fully Report
Profitable
Rapidly Growing Revenue
Costco
Medicare
Medicaid
VA
Coventry
APS
All addS up to REVENUE$$$$$$$$$$$$$$$$$$
ADMD printing presses are on overdrive, expect a RS coming.
Rapidly Growing Revenue M.D.H.I. 10-K ((( PROFITABLE ))) 533% Gross Revenue UP YOY :))))
http://biz.yahoo.com/e/141103/mdhi10-k.html
4.5 stars out of 5 at Costco
http://reviews.costco.com/2070/11748169/medipendant-medipendant-medical-alarm-system-reviews/reviews.htm
Commercial, MediPendant Medical Alarm - at www.costco.com
2015 will be EPIC year 4 MDHI- NOBODY Cares about the past, lmao, SEC NON ISSUE, Scare tactics won't stop MDHI $ales or REVENUE$$$$, 2015 filing will show it ALL, that's why MDHI CEO Ronnie Adams brought it current, after all he did build a $60 Million Dollar NASDQ company. He's done it again, MDHI is CURRENT & PROFITABLE.
Fully Report
Profitable
Rapidly Growing Revenue
Costco
Medicare
Medicaid
VA
Coventry
APS
All addS up to REVENUE$$$$$$$$$$$$$$$$$$
Revenue TRUMP$ ALL- UP 533% and CLIMBING, $MDHI 3 New$ Alerts: 10-K, 533% Increase in Gross Profits YOY, Commercials for November, this company has turned it around, NO STOPPING IT NOW!
$MDHI News: Announces Month-Long, 2-MinuteCommercial Airing on Cablevision's News12 in November,
http://finance.yahoo.com/news/medical-alarm-concepts-holding-inc-172600353.html
or 15' or 14's or 13's or 12's or 11's or 10's or 000's
$MDHI Video, UnderValued, Fully Reporting, Profitable, 5M Float, Low Debt, Costco,Coventry,Medicare,Medicaid,Gross Rev's Rapidly Growing UP 533% YOY.
PPS will be in $ land just on fundamentals and technicals alone, then there is the REVENUE, it's grows 24/7/365
$MDHI Video, UnderValued, Fully Reporting, Profitable, 5M Float, Low Debt, Costco,Coventry,Medicare,Medicaid,Gross Rev's Rapidly Growing UP 533% YOY.
PPS will be in $ land just on fundamentals and technicals alone, then there is the REVENUE, it's grows 24/7/365
This is a BUY and HOLD for 2015 filing$, a real company, product, technology (only 3 way pendant)
MDHI Strong ((( FULLY REPORTING & PROFITABLE ))) 10K- 533% Gross Revenue UP YOY :))))
100% SEC Compliant, scare tactics can't stop REVENUE$ and that's ALL that investors care about.
http://biz.yahoo.com/e/141103/mdhi10-k.html
4.5 stars out of 5 at Costco
http://reviews.costco.com/2070/11748169/medipendant-medipendant-medical-alarm-system-reviews/reviews.htm
Commercial, MediPendant Medical Alarm - at www.costco.com
Time to sell, wash trading, company dumping, warrants, insiders, and the ever cool ihub groups pumping the snot outta this, all adds up to a sell, reload in the 000's
This isn't made up, BILLIONS of Shares.
******ADMD Increased the A/S.to.cover.all.the.ongoing.Toxic Convertible.debt.
During the period ended September 30, 2014 some note holders who opted for conversion were unable to convert their note balances due to there not being enough authorized shares, however, the Company held a Special Meeting of Stockholders on October 28, 2014 on a proposal to approve an amendment to the Company’s Certificate of Incorporation to increase the authorized shares of Common Stock from 500,000,000 to 2,000,000,000 shares.
The stockholders of the Company voted to approve this proposal.
In October 2014 the Company received $31,000 in exchange for a convertible 10%, one year note. The note plus interest is convertible at the option of the note holder into common stock share at $0.046 per share. In addition the Company issued the note holder 12,400 shares of its common stock as a loan origination fee.
During the month of October 2014 the Company issued 55,765,326 shares of unrestricted stock in exchange for convertible debt raised in 2013 and 2014. The Company also issued 1,473,780 shares of unrestricted stock in exchange for the accrued interest on the convertible debt that was converted.
During the month of October 2014 the Company issued 19,585,714 shares of unrestricted stock in exchange for warrants related to convertible debt raised in 2013 and 2014.
During the month of November 2014 the Company issued 66,135,716 shares of unrestricted stock in exchange for convertible debt raised in
2013 and 2014. The Company also issued 1,647,599 shares of unrestricted stock in exchange for the accrued interest on the convertible debt that was converted.
During the month of November 2014 the Company issued 63,523,809 shares of unrestricted stock in exchange for warrants related to convertible debt raised in 2013 and 2014.
ADMD is CONVERTIBLE NOTE Overloaded
Source: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10303489
(1) The Company borrowed $50,000 January 2014, due January 2015. The holder of the note has the right, after the first one hundred eighty days of the note (July 16, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.07 or 58% of the lowest trade price in the 10 trading days previous to the conversion. The Company recorded a debt discount of $46,249 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $1,797 interest expense was recorded, and total amortization of $46,249 was recorded resulting in a debt discount of $0 at September 30, 2014.
(2) The Company borrowed $50,000 January 2014, due January 2015. The holder of the note has the right, after the first one hundred eighty days of the note (July 27, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.09 or 58% of the lowest trade price in the 10 trading days previous to the conversion. The Company recorded a debt discount of $49,636 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $2,685 interest expense was recorded, and total amortization of $26,556 was recorded resulting in a debt discount of $23,080 at September 30, 2014.
(3) The Company borrowed $55,500 January 2014, due October 2014. The holder of the note has the right, after the first one hundred eighty days of the note (July 21, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.28 or 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note during the first ninety days following the date of the note. During that time the amount of any prepayment would equal 111.2% of the outstanding principal balance of the note ($61,716) with no interest on the note. The Company recorded a debt discount of $55,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $55,500 resulting in a debt discount of $0 at September 30, 2014.
(4) The Company borrowed $55,500 January 2014, due October 2014. The holder of the note has the right, after the first one hundred eighty days of the note (July 23, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.28 or 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note during the first ninety days following the date of the note. During that time the amount of any prepayment would equal 111.2% of the outstanding principal balance of the note ($61,716) with no interest on the note. The Company recorded a debt discount of $50,000 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $43,241 resulting in a debt discount of $6,759 at September 30, 2014.
(5) The Company borrowed $50,000 January 2014, due January 2015. The holder of the note has the right, after the first one hundred eighty days of the note (July 27, 2014), to convert the note and accrued interest into common stock at a price per share equal to 40% of the lowest trade price in the 15 trading days previous to the conversion. The Company recorded a debt discount of $50,000 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $2,532 interest expense was recorded, and total amortization of $50,000 was recorded resulting in a debt discount of $0 at September 30, 2014.
12
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 8: CONVERTIBLE NOTES PAYABLE – continued
(6) The Company borrowed $50,000 February 2014, due February 2015. The holder of the note has the right, after the first one hundred eighty days of the note (August 10, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.07 or 58% of the lowest trade price in the 10 trading days previous to the conversion. The Company recorded a debt discount of $37,307 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $1,523 interest expense was recorded, and total amortization of $37,307 was recorded resulting in a debt discount of $0 at September 30, 2014.
(7) The Company borrowed $46,080 February 2014, due February 2015. The holder of the note has the right, after the first one hundred eighty days of the note (August 10, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.08 or 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note during the first ninety days following the date of the note. The Company recorded a debt discount of $42,653 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $42,653 resulting in a debt discount of $0 at September 30, 2014.
(8) The Company borrowed $28,800 February 2014, due February 2015, with a one-time interest charge of 10%. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.195 or 60% of the lowest trade price in the 25 trading days previous to the conversion. The note has an original issue discount of $2,800 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $28,800 related to the conversion feature and original issue discount, along with a derivative liability at inception. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, interest expense of $734 was recorded, and total amortization of $22,877 was recorded resulting in a debt discount of $5,923 at September 30, 2014.
(9) The Company borrowed $51,700 February 2014, due February 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.16 or 55% of the lowest trade price in the 20 trading days previous to the conversion. The note has an original issue discount of $3,300 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $51,700 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $605 of interest expense was recorded, and total amortization of $47,447 was recorded resulting in a debt discount of $4,253 at September 30, 2014.
(10) The Company borrowed $37,500 March 2014, due December 2014, with interest at 8%. The holder of the note has the right, after the first one hundred eighty days of the note (September 16, 2014), to convert the note and accrued interest into common stock at a price per share equal to 61% (representing a discount rate of 39%) of the average of the lowest five trading prices for the Common Stock during the ten trading day period ending one trading day prior to the date of Conversion Notice. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of any prepayment during the first sixty days is 130% of the outstanding amounts owed while the amount of the prepayment increases every subsequent thirty days to 135%, 140%, 145%, and 150% of the outstanding amounts owed. The Company recorded a debt discount of $37,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the eighteen month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $21,411 resulting in a debt discount of $16,089 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $1,595 was recorded for the note.
13
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 8: CONVERTIBLE NOTES PAYABLE – continued
(11) The Company borrowed $50,000 March 2014, due March 2015. The holder of the note has the right, after the first one hundred eighty days of the note (September 18, 2014), to convert the note and accrued interest into common stock at a price per share equal to 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company recorded a debt discount of $50,000 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, $2,512 of interest expense was recorded, and total amortization was recorded in the amount of $27,624 resulting in a debt discount of $22,376 at September 30, 2014.
(12) The Company borrowed $165,910 March 2014, due April 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to the lesser of $1.00 or 65% of the average of the three lowest trading prices in the 20 trading days previous to the conversion. The note has an original issue discount of $16,450 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $163,394 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $5,760 of interest expense was recorded, and total amortization of $91,470 was recorded resulting in a debt discount of $71,924 at September 30, 2014.
(13) The Company borrowed $32,000 April 2014, due April 2015. The holder of the note has the right, after the first one hundred eighty days of the note (October 1, 2014), to convert the note and accrued interest into common stock at a price per share equal to 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company recorded a debt discount of $27,143 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $11,681 resulting in a debt discount of $15,462 at September 30, 2014.
(14) The Company borrowed $46,080 April 2014, due April 2015. The holder of the note has the right, after the first one hundred eighty days of the note (October 11, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.08 or 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note during the first ninety days following the date of the note. The Company recorded a debt discount of $46,080 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $21,336 resulting in a debt discount of $24,744 at September 30, 2014.
(15) The Company borrowed $42,500 May 2014, due February 2015, with interest at 8%. The holder of the note has the right, after the first one hundred eighty days of the note (November 16, 2014), to convert the note and accrued interest into common stock at a price per share equal to 61% (representing a discount rate of 39%) of the average of the lowest five trading prices for the Common Stock during the ten trading day period ending one trading day prior to the date of Conversion Notice. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of any prepayment during the first sixty days is 130% of the outstanding amounts owed while the amount of the prepayment increases every subsequent thirty days to 135%, 140%, 145%, and 150% of the outstanding amounts owed. The Company recorded a debt discount of $42,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the nine month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $18,419 resulting in a debt discount of $24,081 at June 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $1,248 was recorded for the note.
14
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 8: CONVERTIBLE NOTES PAYABLE – continued
(16) The Company borrowed $55,000 May 2014, due May 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.03 or 55% of the lowest trade price in the 20 trading days previous to the conversion. The note has an original issue discount of $5,000 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $50,000 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $2,170 of interest expense was recorded, and total amortization of $18,082 was recorded resulting in a debt discount of $31,918 at September 30, 2014.
(17) The Company borrowed $37,500 June 2014, due March 2015, with interest at 8%. The holder of the note has the right, after the first one hundred eighty days of the note (December 10, 2014), to convert the note and accrued interest into common stock at a price per share equal to 61% (representing a discount rate of 39%) of the average of the lowest five trading prices for the Common Stock during the ten trading day period ending one trading day prior to the date of Conversion Notice. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of any prepayment during the first sixty days is 130% of the outstanding amounts owed while the amount of the prepayment increases every subsequent thirty days to 135%, 140%, 145%, and 150% of the outstanding amounts owed. The Company recorded a debt discount of $37,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the eighteen month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $12,811 resulting in a debt discount of $24,689 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $896 was recorded for the note.
(18) The Company borrowed $28,800 June 2014, due June 2015. The holder of the note has the right, after the first one hundred eighty days of the note (December 20, 2014), to convert the note and accrued interest into common stock at a price per share equal to the lesser of $0.08 or 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note during the first ninety days following the date of the note. The Company recorded a debt discount of $28,800 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $7,811 resulting in a debt discount of $20,989 at September 30, 2014.
(19) The Company borrowed $40,000 June 2014, due June 2015. The holder of the note has the right, after the first one hundred eighty days of the note (December 23, 2014), to convert the note and accrued interest into common stock at a price per share equal to 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of the prepayment is 145% of the outstanding amounts owed. The Company recorded a debt discount of $40,000 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $10,520 resulting in a debt discount of $29,480 at September 30, 2014.
(20) The Company borrowed $40,000 June 2014, due June 2015. The holder of the note has the right, after the first one hundred eighty days of the note (December 23, 2014), to convert the note and accrued interest into common stock at a price per share equal to 60% of the lowest trade price in the 25 trading days previous to the conversion. The Company has the right to prepay the note and accured interest during the first one hundred eighty days following the date of the note. During that time the amount of any repayment is 145% of the outstanding amounts owed. The Company recorded a debt discount of $40,000 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $438 resulting in a debt discount of $39,562 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $1,052 was recorded for the note.
15
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 8: CONVERTIBLE NOTES PAYABLE – continued
(21) The Company borrowed $56,589 July 2014, due July 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to the lesser of $1.00 or 65% of the average of the three lowest trading prices in the 20 trading days previous to the conversion. The note has an original issue discount of $5,611 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $56,589 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $0 of interest expense was recorded, and total amortization of $14,264 was recorded resulting in a debt discount of $42,325 at September 30, 2014.
(22) The Company borrowed $37,500 June 2014, due July 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to 50% of the lowest of the lowest trading price in the 15 trading days previous to the conversion. The Company recorded a debt discount of $37,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the twelve month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $7,005 resulting in a debt discount of $30,495 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $838 was recorded for the note.
(23) The Company borrowed $37,500 July 2014, due April 2015, with interest at 8%. The holder of the note has the right, after the first one hundred eighty days of the note (January 5, 2015), to convert the note and accrued interest into common stock at a price per share equal to 61% (representing a discount rate of 39%) of the average of the lowest five trading prices for the Common Stock during the ten trading day period ending one trading day prior to the date of Conversion Notice. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of any prepayment during the first sixty days is 130% of the outstanding amounts owed while the amount of the prepayment increases every subsequent thirty days to 135%, 140%, 145%, and 150% of the outstanding amounts owed. The Company recorded a debt discount of $37,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the eighteen month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $8,630 resulting in a debt discount of $28,870 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $690 was recorded for the note.
(24) The Company borrowed $22,500 June 2014, due August 2015, with interest at 8%. The holder of the note has the right, after the first one hundred eighty days of the note (February 2, 2014), to convert the note and accrued interest into common stock at a price per share equal to 61% (representing a discount rate of 39%) of the average of the lowest five trading prices for the Common Stock during the ten trading day period ending one trading day prior to the date of Conversion Notice. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of any prepayment during the first sixty days is 130% of the outstanding amounts owed while the amount of the prepayment increases every subsequent thirty days to 135%, 140%, 145%, and 150% of the outstanding amounts owed. The Company recorded a debt discount of $22,500 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the eighteen month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $5,188 resulting in a debt discount of $17,312 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $271 was recorded for the note.
(25) The Company borrowed $36,750 August 2014, due August 2015, with interest at 10%. The holder of the note has the right, after the first one hundred eighty days of the note (February 10, 2014), to convert the note and accrued interest into common stock at a price per share equal to 60% (representing a discount rate of 40%) of the lowest trading price for the Common Stock during the twenty five trading day period ending one trading day including the date of Conversion Notice. The Company has the right to prepay the note and accrued interest during the first one hundred eighty days following the date of the note. During that time the amount of any prepayment is 145% of the outstanding amounts owed. The Company recorded a debt discount of $36,750 related to the conversion feature of the note, along with a derivative liability at inception. Interest expense for the amortization of the debt discounts is calculated on a straight-line basis over the eighteen month life of the note. During the nine months ending September 30, 2014, total amortization was recorded in the amount of $4,732 resulting in a debt discount of $32,018 at September 30, 2014. Also during the nine months ending September 30, 2014, interest expense of $473 was recorded for the note.
16
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 8: CONVERTIBLE NOTES PAYABLE – continued
(26) The Company borrowed $33,500 August 2014, due February 2015. The Company may prepay the note for a net payment of $33,500 at any time prior to November 27, 2014. After November 27, 2014, the holder has the right to refuse any further payments and to convert this note when it matures, February 27, 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to 40% of the average three lowest trade prices in the 20 trading days previous to the conversion. The note has an original issue discount of $8,500 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $26,387 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $0 of interest expense was recorded, and total amortization of $4,758 was recorded resulting in a debt discount of $21,629 at September 30, 2014.
(76) The Company borrowed $37,500 September 2014, due September 2015. The holder of the note has the right to convert the note and accrued interest into common stock at a price per share equal to 45% of the lowest trade prices in the 15 trading days previous to the conversion. The note has an original issue discount of $5,000 which has been added to the principal balance of the note and is being recognized in interest expense over the life of the note. The Company recorded a debt discount of $37,500 related to the conversion feature and original issue discount. Interest expense for the amortization of the debt discount is calculated on a straight-line basis over the twelve month life of the note. During the nine months ended September 30, 2014, $0 of interest expense was recorded, and total amortization of $1,232 was recorded resulting in a debt discount of $36,268 at September 30, 2014.
The Company issued 10,400 shares of its common stock and a convertible promissory note in the amount of $26,000 with interest payable at 10% per annum in January 2014 to our major stockholder, who is also a Director. The Note matures in January of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.095 per share. The value of the $26,000 debt plus the $0.095 fair market value of the 10,400 shares at the date of the agreement was prorated to arrive at the allocation of the original $26,000 debt and the value of the 10,400 shares and the beneficial conversion feature. The computation resulted in an allocation of $24,096 toward the debt and $952 to the shares and $952 to the beneficial conversion feature. The $952 value of the shares and the $952 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $876 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $24,972 as of June 30, 2014. Additionally, $1,190 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the six months ending June 30, 2014.
In February 2014 the Company issued a 12% Convertible Promissory Note in the amount of $55,000 to an unrelated company. The note calls for a 200,000 restricted shares of the Company’s common stock to be issued a loan fee. The note is not convertible by the holder for the first 180 days, in which time the Company can repay the note plus interest. If the Company repays the note within the first 30 days the interest rate is calculated at 25% of the note balance, if paid between 31 days and 179 days the interest rate is calculated at 35% of the note balance, and if repaid after 180 days the interest rate is calculated at 45% of the note balance.
The Company issued 5,200 shares of its common stock and a convertible promissory note in the amount of $13,000 with interest payable at 10% per annum in April 2014 to our major stockholder, who is also a Director. The Note matures in April of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.095 per share. The value of the $13,000 debt plus the $0.095 fair market value of the 5,200 shares at the date of the agreement was prorated to arrive at the allocation of the original $13,000 debt and the value of the 5,200 shares and the beneficial conversion feature. The computation resulted in an allocation of $12,809 toward the debt and $191 to the shares and $0 to the beneficial conversion feature. The $191 value of the shares and the $0 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $40 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $12,849 as of June 30, 2014. Additionally, $270 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the six months ending June 30, 2014.
In May 2014 the Company issued a 12% Convertible Promissory Note in the amount of $55,000 to an unrelated company. The note calls for a 532,609 restricted shares of the Company’s common stock to be issued a loan fee. The note is not convertible by the holder for the first 180 days, in which time the Company can repay the note plus interest. If the Company repays the note within the first 30 days the interest rate is calculated at 25% of the note balance, if paid between 31 days and 179 days the interest rate is calculated at 35% of the note balance, and if repaid after 180 days the interest rate is calculated at 45% of the note balance.
18
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 10: STOCKHOLDERS’ EQUITY – continued
Common Stock Issued for Convertible Debt – continued
The Company issued 10,400 shares of its common stock and a convertible promissory note in the amount of $26,000 with interest payable at 10% per annum in May 2014 to our major stockholder, who is also a Director. The Note matures in May of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.06 per share. The value of the $26,000 debt plus the $0.06 fair market value of the 10,400 shares at the date of the agreement was prorated to arrive at the allocation of the original $26,000 debt and the value of the 10,400 shares and the beneficial conversion feature. The computation resulted in an allocation of $25,671 toward the debt and $329 to the shares and $0 to the beneficial conversion feature. The $329 value of the shares and the $0 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $40 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $25,711 as of June 30, 2014. Additionally, $325 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the six months ending June 30, 2014.
In May 2014 the Company issued a 12% Convertible Promissory Note in the amount of $55,000 to an unrelated company. The note calls for a 500,000 restricted shares of the Company’s common stock to be issued a loan fee. The note is not convertible by the holder for the first 180 days, in which time the Company can repay the note plus interest. If the Company repays the note within the first 30 days the interest rate is calculated at 25% of the note balance, if paid between 31 days and 179 days the interest rate is calculated at 35% of the note balance, and if repaid after 180 days the interest rate is calculated at 45% of the note balance.
The Company issued 10,400 shares of its common stock and a convertible promissory note in the amount of $26,000 with interest payable at 10% per annum in June 2014 to our major stockholder, who is also a Director. The Note matures in June of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.046 per share. The value of the $26,000 debt plus the $0.046 fair market value of the 10,400 shares at the date of the agreement was prorated to arrive at the allocation of the original $26,000 debt and the value of the 10,400 shares and the beneficial conversion feature. The computation resulted in an allocation of $25,794 toward the debt and $206 to the shares and $0 to the beneficial conversion feature. The $206 value of the shares and the $0 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $10 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $25,804 as of June 30, 2014. Additionally, $110 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the six months ending June 30, 2014.
The Company issued 8,000 shares of its common stock and a convertible promissory note in the amount of $20,000 with interest payable at 10% per annum in July 2014 to our major stockholder, who is also a Director. The Note matures in July of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.046 per share. The value of the $20,000 debt plus the $0.046 fair market value of the 8,000 shares at the date of the agreement was prorated to arrive at the allocation of the original $20,000 debt and the value of the 8,000 shares and the beneficial conversion feature. The computation resulted in an allocation of $19,786 toward the debt and $214 to the shares and $0 to the beneficial conversion feature. The $214 value of the shares and the $0 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $50 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $19,836 as of September 30, 2014. Additionally, $400 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the nine months ending September 30, 2014.
The Company issued 10,400 shares of its common stock and a convertible promissory note in the amount of $26,000 with interest payable at 10% per annum in August 2014 to our major stockholder, who is also a Director. The Note matures in August of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.046 per share. The value of the $26,000 debt plus the $0.046 fair market value of the 10,400 shares at the date of the agreement was prorated to arrive at the allocation of the original $26,000 debt and the value of the 10,400 shares and the beneficial conversion feature. The computation resulted in an allocation of $25,855 toward the debt and $145 to the shares and $0 to the beneficial conversion feature. The $145 value of the shares and the $0 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $18 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $25,873 as of September 30, 2014. Additionally, $325 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the nine months ending September 30, 2014.
19
Advanced Medical Isotope Corporation
Notes to Condensed Financial Statements
For the nine months ended September 30, 2014 (unaudited) and the year ended December 31, 2013
NOTE 10: STOCKHOLDERS’ EQUITY – continued
Common Stock Issued for Convertible Debt – continued
The Company issued 9,200 shares of its common stock and a convertible promissory note in the amount of $23,000 with interest payable at 10% per annum in September 2014 to our major stockholder, who is also a Director. The Note matures in September of 2015. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the maturity date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.046 per share. The value of the $23,000 debt plus the $0.046 fair market value of the 9,200 shares at the date of the agreement was prorated to arrive at the allocation of the original $23,000 debt and the value of the 9,200 shares and the beneficial conversion feature. The computation resulted in an allocation of $22,954 toward the debt and $46 to the shares and $0 to the beneficial conversion feature. The $46 value of the shares and the $0 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $2 has been accrued and added to the note payable bringing the total debt balance related to this convertible promissory note to $22,956 as of September 30, 2014. Additionally, $96 worth of interest expense on the notes principal balance has been recognized in the accompanying financial statements for the nine months ending September 30, 2014.
2015 will be EPIC, looking forward to U.P.M Deal to CLO$E
UNLIMITED shares is spot on, they got BILLIONS to Dump
Guess I was right, HEADED LOWER
No scare, HEADED LOWER on fundamentals :)
This will see some lower dips, a billion shares are being dumped. I'll add if it sees a nice pull back, we could see .001's again.
Watch for sell off and some dilution from the company, add on the dip.
ADMD is a printing press, so play it as such.
MDHI News -- Current State and Growth Initiatives
((( Fully Reporting-Profitable-Rapidly Growing )))
http://finance.yahoo.com/news/medical-alarm-concepts-current-state-080833056.html
KING OF PRUSSIA, Pa., Dec. 17, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Medical Alarm Concepts Holding, Inc. (MDHI) (the "Company"), is the manufacturer of the first fully-monitored medical alarm system that allows the user to speak and listen directly through the pendant. Today, President and CEO, Ronald Adams, provides investors with an update on the current state of the Company.
The Company has updated its financial reporting, made 16 filings within the past 12 months, is now current in its filings and is fully compliant in its reporting as publicly traded OTC Company.
In order to become a profitable operation, MDHI has issued additional stock to convert highly leveraged debt and improve its balance sheet. As a direct result of the costs associated with the stock conversion, Selling, General, and Administrative expenses for the year ending June 30, 2014 increased. This was a one-time event. The associated expenses will not appear in upcoming financials. All the derivative liabilities and the underlying warrants that have been part of our financial statements for the past few years are no longer a part of MDHI and its capital structure. All have been retired as a result of the conversion of the debt to equity.
The working capital deficit mentioned in our filings has not increased significantly over the past year, and the stockholders' deficit has remained fairly constant as well. Management believes that the Company has made a tremendous turnaround in the past 12 months and we continue to work to improve our financial condition. Management anticipates that the Company will soon be in a position to announce its plans to launch a new product line which will increase revenue and improve productivity.
We anticipate increased sales in 2015. The Company has entered into distribution agreements in several countries and anticipates its sales to increase in 2015 from its international channels. The Company's anticipated increased sales will also come from new initiatives and product line. To clarify this further, a significant amount resources have been deployed on the development of a new, innovative, and technically-advanced product. The product has been designed, tested, and is currently being manufactured.
The Company has developed a new business model that incorporates not only the launch of this new product through several initiatives, but also a plan to grow the business through acquisitions.
Additional personnel have been hired to help implement these programs. These include:
Principal Engineer - with over 20 years of relevant experience, the Principal Engineer is responsible for evaluating and recommending new technologies in the industry as well as overseeing the development of new products for the Company;
Director of Strategic Partnerships -- The Director of Strategic Partnerships has owned and operated PERS (Personal Emergency Response System) businesses and has been active in the Senior Care market for over 19 years. The primary responsibility of the Director is to manage the Company's strategic acquisitions and to develop and implement the sales and marketing plan for new products and services;
-and -
Vice President of Operations - with over 10 years of experience in systems and software design, programming, integration, implementation, and support, the VP of Operations is responsible for the design and development of all internal/external systems for new and existing products and programs.
The increase in Company expenses in the last quarter has been a direct result of the re-alignment of the Company's business model. These were expensed, not capitalized. While we anticipate an increase in overhead, management is optimistic that these changes will lead to an increase in sales and profit, and that increase will exceed the additional overhead charges.
"It is the time of the year to give thanks, so we would like to take this opportunity to thank our investors for standing by MDHI, and for helping us to get to where we are today. I am certain that 2015 will be a successful year for our Company. Happy Holidays to you and your families." -- Ronnie Adams, CEO and President, MDHI.
About Medical Alarm Concepts Holding, Inc.
Medical Alarm Concepts Holdings, Inc., a publicly traded company under the symbol MDHI, is the creator of the MediPendant(R) a patented two-way and three-way voice technology, for the personal medical alarm marketplace. The MediPendant(R) has been featured in nationally renowned retailer Costco Wholesale Corporation since 2011 and has received 28 product reviews on the retailer's website, 21 of which are "5 out of 5 Star" ratings. The average rating is "4.5 Stars" out of 5 Stars.
For more information, please visit our website at http://www.medipendant.com.
Safe Harbor Statement
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.
CONTACT
Medical Alarm Concepts Holding, Inc.
info(at)medalarmco(dot)com
877-639-2929 Ext 113
SOURCE: Medical Alarm Concepts Holding, Inc.
Report TOS
MDHI News -- Current State and Growth Initiatives
((( Fully Reporting-Profitable-Rapidly Growing )))
http://finance.yahoo.com/news/medical-alarm-concepts-current-state-080833056.html
KING OF PRUSSIA, Pa., Dec. 17, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Medical Alarm Concepts Holding, Inc. (MDHI) (the "Company"), is the manufacturer of the first fully-monitored medical alarm system that allows the user to speak and listen directly through the pendant. Today, President and CEO, Ronald Adams, provides investors with an update on the current state of the Company.
The Company has updated its financial reporting, made 16 filings within the past 12 months, is now current in its filings and is fully compliant in its reporting as publicly traded OTC Company.
In order to become a profitable operation, MDHI has issued additional stock to convert highly leveraged debt and improve its balance sheet. As a direct result of the costs associated with the stock conversion, Selling, General, and Administrative expenses for the year ending June 30, 2014 increased. This was a one-time event. The associated expenses will not appear in upcoming financials. All the derivative liabilities and the underlying warrants that have been part of our financial statements for the past few years are no longer a part of MDHI and its capital structure. All have been retired as a result of the conversion of the debt to equity.
The working capital deficit mentioned in our filings has not increased significantly over the past year, and the stockholders' deficit has remained fairly constant as well. Management believes that the Company has made a tremendous turnaround in the past 12 months and we continue to work to improve our financial condition. Management anticipates that the Company will soon be in a position to announce its plans to launch a new product line which will increase revenue and improve productivity.
We anticipate increased sales in 2015. The Company has entered into distribution agreements in several countries and anticipates its sales to increase in 2015 from its international channels. The Company's anticipated increased sales will also come from new initiatives and product line. To clarify this further, a significant amount resources have been deployed on the development of a new, innovative, and technically-advanced product. The product has been designed, tested, and is currently being manufactured.
The Company has developed a new business model that incorporates not only the launch of this new product through several initiatives, but also a plan to grow the business through acquisitions.
Additional personnel have been hired to help implement these programs. These include:
Principal Engineer - with over 20 years of relevant experience, the Principal Engineer is responsible for evaluating and recommending new technologies in the industry as well as overseeing the development of new products for the Company;
Director of Strategic Partnerships -- The Director of Strategic Partnerships has owned and operated PERS (Personal Emergency Response System) businesses and has been active in the Senior Care market for over 19 years. The primary responsibility of the Director is to manage the Company's strategic acquisitions and to develop and implement the sales and marketing plan for new products and services;
-and -
Vice President of Operations - with over 10 years of experience in systems and software design, programming, integration, implementation, and support, the VP of Operations is responsible for the design and development of all internal/external systems for new and existing products and programs.
The increase in Company expenses in the last quarter has been a direct result of the re-alignment of the Company's business model. These were expensed, not capitalized. While we anticipate an increase in overhead, management is optimistic that these changes will lead to an increase in sales and profit, and that increase will exceed the additional overhead charges.
"It is the time of the year to give thanks, so we would like to take this opportunity to thank our investors for standing by MDHI, and for helping us to get to where we are today. I am certain that 2015 will be a successful year for our Company. Happy Holidays to you and your families." -- Ronnie Adams, CEO and President, MDHI.
About Medical Alarm Concepts Holding, Inc.
Medical Alarm Concepts Holdings, Inc., a publicly traded company under the symbol MDHI, is the creator of the MediPendant(R) a patented two-way and three-way voice technology, for the personal medical alarm marketplace. The MediPendant(R) has been featured in nationally renowned retailer Costco Wholesale Corporation since 2011 and has received 28 product reviews on the retailer's website, 21 of which are "5 out of 5 Star" ratings. The average rating is "4.5 Stars" out of 5 Stars.
For more information, please visit our website at http://www.medipendant.com.
Safe Harbor Statement
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.
CONTACT
Medical Alarm Concepts Holding, Inc.
info(at)medalarmco(dot)com
877-639-2929 Ext 113
SOURCE: Medical Alarm Concepts Holding, Inc.
Fully Reporting & Profitable MDHI 100% SEC COMPLIANT, FULLY Reporting, CURRENT :)
Scare antics to bring up the past not working, NO SELLOFF. Nobody cares about JN, who's he again ??? lol
PPS Headed HIGHER on 24/7/365 $ales
MDHI is ALL about the FUTURE REVENUE, 2015 :))))
$MDHI Video, UnderValued, Fully Reporting, Profitable, 5M Float, Low Debt, Costco,Coventry,Medicare,Medicaid,Gross Rev's Rapidly Growing UP 533% YOY.
Costco + MediPendant = 533% INCREASE IN REVENUE$$$$$
"could" ?? sure doesn't sound like you hired a forensic account then, or that the sec is actively pursuing Ronnie, lmao
Means ZERO, but REVENUE UP 533% sure means something, that MDHI is PROFITABLE and FULLY REPORTING and 2015 will be HUGE REVENUE YEAR $$$$$$$$$$$$$$$$$
lol :))))
M.D.H.I. 10-K ((( PROFITABLE & FULLY REPORTING ))) 533% Gross Revenue UP YOY )))
$ALES 24/7/365 = rapidly increasing recurring REVENUE Stream
http://biz.yahoo.com/e/141103/mdhi10-k.html
4.5 stars out of 5 at Costco
http://reviews.costco.com/2070/11748169/medip...eviews.htm
Commercial, MediPendant Medical Alarm - at www.costco.com
No SEC investigation, No Forensic accountant hired, just more scare tactics which are not working and CAN'T STOP REVENUE$$$$$$$$$$$$$$
LMAO, but we do have MotorPillz for those that lost on that RS:)))))
LMAO
MDHI Strong ((( FULLY REPORTING & PROFITABLE ))) 10K- 533% Gross Revenue UP YOY :))))
100% SEC Compliant, scare tactics can't stop REVENUE$ and that's ALL that investors care about.
http://biz.yahoo.com/e/141103/mdhi10-k.html
4.5 stars out of 5 at Costco
http://reviews.costco.com/2070/11748169/medipendant-medipendant-medical-alarm-system-reviews/reviews.htm
Commercial, MediPendant Medical Alarm - at www.costco.com
MDHI Strong ((( FULLY REPORTING & PROFITABLE ))) 10K- 533% Gross Revenue UP YOY :))))
100% SEC Compliant, scare tactics can't stop REVENUE$ and that's ALL that investors care about.
http://biz.yahoo.com/e/141103/mdhi10-k.html
4.5 stars out of 5 at Costco
http://reviews.costco.com/2070/11748169/medipendant-medipendant-medical-alarm-system-reviews/reviews.htm
Commercial, MediPendant Medical Alarm - at www.costco.com
PS, I grabbed those CHEAPIES, thank you to whoever is trying to drop pps, it WILL close back above .34pps
MM are loading up, they know 2015 will be HUGE :)))))
Fully Reporting & Profitable, scare tactics couldn't stop a 533% INCREASE IN REVENUES YOY, and the scare tactic on the SEC is laughable.
LMAO
$MDHI, Fully Reporting & Profitable, Zero Debt, Sales 24/7/365, Rapidly Growing Recurring Revenue Stream.
TRADING SHARES IN FLOAT: 1.2 MILLION
TOTAL OUTSTANDING: 5,518,541
MediPendant #1 at Costco, only 3 way PERS on market.
$MDHI, Fully Reporting & Profitable, Zero Debt, Sales 24/7/365, Rapidly Growing Recurring Revenue Stream.
TRADING SHARES IN FLOAT: 1.2 MILLION
TOTAL OUTSTANDING: 5,518,541
MediPendant #1 at Costco, only 3 way PERS on market.
MDHI 100% SEC Compliant, Fully Reporting & Profitable, Costco only works with the BEST, MediPendant Rated #1 PERS, Sales / Revenue Rapidly Growing 24/7/365
Watch for next filing, they tell the truth and REVENUE Trumps ALL!